Aurobindo Pharma Q2 profit seen up 15% to Rs 696 cr, operating margin may grow 110 bps



EBITDA (earnings before interest, tax, depreciation and amortisation) may increase 15.6 percent year-on-year to Rs 1,074.4 crore and margin may expand 110 basis points to 25.7 percent for quarter ended September 2017.